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Abstract 
 
Anticoagulation for atrial fibrillation has become more complex due to the introduction of new 
anticoagulant agents, the number and kinds of patients requiring therapy, and the interactions of 
those patients in the matrix of care. The management of anticoagulation has become a “team 
sport” involving multiple specialties in multiple sites of care. The American College of 
Cardiology, through the College’s Anticoagulation Initiative, convened a roundtable of experts 
from multiple specialties to discuss topics important to the management of patients requiring 
anticoagulation and to make expert recommendations on issues such as the initiation and 
interruption of anticoagulation, quality of anticoagulation care, management of major and minor 
bleeding, and treatment of special populations. The attendees continued to work toward 
consensus on these topics, and present the key findings of this roundtable in a state-of- the-art 
review focusing on the practical aspects of anticoagulation care for the patient with atrial 
fibrillation. 
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INTRODUCTION 
In September 2013, following a series of pivotal trials and drug approvals, the American College 
of Cardiology (ACC) convened a roundtable discussion at Heart House to address clinical issues 
regarding oral anticoagulant alternatives to warfarin in patients with nonvalvular atrial 
fibrillation (AF). The meeting included representatives of specialty societies, the U.S. Food and 
Drug Administration (FDA), industry, and patient advocates (Appendix 1). Discussions covered 
4 general topics: 
1) Initiation and interruption of anticoagulant therapy 
2) Quality, cost and team-based management of anticoagulation 
3) Management of bleeding and emergency care 
4) Complex disease states and special populations 
Discussion was supplemented with focused literature reviews of the English language literature 
in Pub Med to November, 2014 that pertained to the roundtable themes. 
Data from the ACC PINNACLE Registry showed large variations in percentage of appropriate 
anticoagulation for AF even before the introduction of direct acting oral anticoagulants (DOACs) 
(1). Management of anticoagulation crosses the bounds of specialty and type of practice 
(Central Illustration). This review attempts to provide practical consensus recommendations as 
well as to point out gaps in knowledge and areas of future inquiry. 
ASSESSING BENEFITS AND RISKS OF ORAL ANTICOAGULANTS 
Oral anticoagulant therapy (OACT) reduces stroke risk in patients with non-valvular AF. 
Patients with valvular AF and those with prosthetic mechanical heart valves or significant 
(moderate to severe) mitral stenosis were excluded from clinical trials, and therefore this 
document will not suggest changes in their management. Patients with non-valvular AF 
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(paroxysmal, persistent, or permanent) with or without symptoms are all considered for OAC 
based on their individual risk profile.  
The 2014 AF guidelines recommend the use of CHA2DS2-VASc scoring system (Table 1) (2) 
instead of CHADS2 (3), because it increases the number of patients who meet criteria for 
anticoagulation therapy while more accurately identifying truly low risk patients.  Many patients, 
(women, those aged 65-75, and patients with vascular disease) are redistributed from the low- to 
higher-risk categories (3). 
Several bleeding risk scores are available including HAS-BLED and ATRIA (4, 5), which may 
identify patients at higher risk of bleeding; however, more information is needed on their clinical 
utility (2). Tools, such as the AnticoagEvaluator and the Stroke Prevention in Atrial Fibrillation 
Risk Tool, are available at the point of care to estimate risk of stroke and benefits of 
anticoagulation therapy in patients with AF (6, 7).  
CLINICAL TRIALS COMPARING DOACS WITH VITAMIN K ANTAGONISTS  
There are 2 classes of DOACs: factor Xa (FXa) inhibitors such as rivaroxaban, apixaban and 
edoxaban, and direct thrombin inhibitors  such as dabigatran. Table 2 highlights selected trials 
comparing safety and efficacy of DOACs to adjusted dose warfarin with target INR of 2-3.  
These trials have limitations, including noninferiority study designs and relatively short 
treatment follow-up. The median time in therapeutic range (TTR) for warfarin patients was ≤ 
69% in each of the trials; the results may have been different if the patients had achieved a 
greater percentage of TTR. Limited guidance is provided concerning the potential advantage of 
using DOACs in patients on warfarin with TTR > 75%. When data from the trials are combined, 
DOACs appear to reduce stroke, intracranial hemorrhage (ICH), and overall mortality compared 
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to warfarin, with similar major bleeding risks. On the other hand, gastrointestinal bleeding 
appears increased with rivaroxaban, edoxaban 60 mg, and dabigatran compared to warfarin (8).  
THE RIGHT DRUG FOR THE RIGHT PATIENT 
Appropriate drug selection depends on approved indications, patient characteristics, concomitant 
medications, clinician and patient preference, and cost. Therapy with well-managed warfarin and 
with high TTR is appropriate for certain patients. Several reports quantify the relationship 
between TTR and major clinical outcomes in patients with AF (9, 10). Patients with TTR < 58% 
despite adequate warfarin dosing adjustment may benefit from a DOAC (11). Clinical trials have 
also shown lower risks of intracranial hemorrhage (ICH) with DOACs when compared to 
warfarin.  
Individual response to warfarin varies with age, gender, body mass index, concomitant meds, 
certain foods, and genotype. Warfarin has a relatively narrow therapeutic index. Overdosing can 
result in bleeding; under dosing can result in thrombosis. Patients treated with warfarin should 
have an INR determined at least weekly during initiation of therapy, and regular ongoing 
monitoring when INR is stable and within range. Genetics influence VKA response; however, 
genetic testing to predict VKA response has not been widely adopted nor has it been shown to be 
of value in randomized trials (12, 13). Home monitoring of VKA therapy is reasonable in 
selected patients (14) including those who have difficult access to lab services. Many insurance 
plans, including Medicare, cover the cost of a device and once-weekly use of test strips. Several 
nationwide VKA home management services accept commercial and Medicare health insurance 
(15).   
The DOACs’ mechanism of action, dosing information, drug interactions, and recommended 
monitoring schedules are listed in Table 3. Although DOACs are more expensive than warfarin, 
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advantages for some patients include a lack of dietary limitations, fewer drug interactions and 
elimination of INR testing.  
Patients taking OACs require baseline and periodic lab monitoring (16). DOAC dosing is 
sensitive to changes in renal function.  A summary of dosing changes relative to renal function 
can be found in Table 3.  Although many laboratories report renal function as the estimated 
glomerular filtration rate (eGFR), renal function should be estimated using the Cockcroft-Gault 
equation, [(140-age)x(weight in kg)x(0.85 if female)/(72)x(creatinine in mg/dL)] to determine 
the appropriate DOAC dose.  
Patients with severe renal impairment were excluded from the large phase III trials evaluating 
DOACs, and therefore warfarin remains the treatment of choice for AF patients with severe renal 
impairment or end-stage renal disease (2).  However, the FDA has approved apixaban in patients 
with end-stage renal disease on hemodialysis based on pharmacokinetic modeling data.  
DRUG INTERACTIONS 
Drug interactions should be considered when prescribing any oral anticoagulant therapy (OACT) 
(Tables 3, 4). All patients should be instructed to alert the clinician prescribing the OACT any 
time changes in other medications are made (Table 5). Warfarin has many food and drug 
interactions (17) although some are not well documented. Non-prescription medications, e.g. 
acetaminophen, fish oil, herbal supplements and grapefruit juice, can potentiate the effect of 
VKAs (18-21). 
DOACs are also subject to drug interactions.  Rivaroxaban and apixaban interact with drugs that 
are strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and are impacted by the 
efflux transporter P-glycoprotein (22) . Rifampin, a P-glycoprotein inducer, should not be used 
with edoxaban or dabigatran. Medications that inhibit the P-glycoprotein system increase 
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dabigatran and edoxaban plasma concentrations.  Concomitant use of quinidine, dronedarone, or 
verapamil with edoxaban significantly increase edoxaban exposure (23). Although the dose of 
edoxaban was reduced by 50% in patients on concomitant verapamil, quinidine, or dronedarone 
in ENGAGE AF-TIMI 48, the FDA does not recommend dose reduction in patients who are 
taking concomitant P-gp inhibitors (24). Patients on antiretroviral therapy, cyclosporine, azole 
antifungals, and macrolides were excluded from ENGAGE AF-TIMI 48 and their use in patients 
on DOACs should be avoided as they increase edoxaban concentrations.  
INTERRUPTION OF DRUG THERAPY  
Short-term interruption of OACT is safe for most low risk invasive procedures.  Management of 
OACT should be individualized for patients at higher thromboembolic risk who are undergoing 
high-risk procedures. Procedures that pose a high risk of bleeding include intracranial, 
intraspinal, retroperitoneal or intrathoracic surgery.  Intraocular procedures and neuraxial 
anesthesia may present risks to patients with even minor bleeding. Bridging with a parenteral 
agent, e.g. unfractionated heparin or low molecular weight heparin, is common but the data on 
prevention of embolic events are limited and the rate of bleeding is significantly increased (25). 
The decision to bridge must balance the risk of an embolic event against the risk of bleeding 
(26). 
TRANSITIONING BETWEEN ANTICOAGULANTS 
The INR monitoring is needed when transitioning patients from VKA to a DOAC, to avoid over-
anticoagulation. INR targets when switching from warfarin to a DOAC are summarized in Table 
4. If switching from a DOAC to VKA, bridging with a short-acting parenteral agent or a lower 
dose of the DOAC may be needed. INR should be at least twice weekly and VKA dose adjusted 
using a reliable algorithm until the INR reaches 2.0 to avoid excess bleeding or thrombotic 
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events (27). When transitioning from parenteral agents to DOACs, the DOACs can be initiated 
up to 2 hours before the next dose of the parenteral agent or when stopping the intravenous (IV) 
infusion. For those patients transitioning from FXa inhibitors to parenteral agents, the parenteral 
agents can be started at the intended time for the next dose of FXa inhibitor. When converting 
from dabigatran to a parenteral agent, the starting time is dependent on the patient’s creatinine 
clearance (Table 5). 
LONG-TERM MANAGEMENT OF OACT 
National guidelines and regulatory agencies endorse coordinated-care anticoagulation 
management models to maximize patient outcomes (14, 28-31). Despite data showing that 
coordinating care through anticoagulation clinics (ACs) improves patient outcomes and reduces 
costs when compared to usual medical care (14, 28, 29), only 30-40% of patients on VKAs are 
managed in an AC (32).  
The scope of AC services should include management of DOACs (32). Therapy with both 
DOACs and VKAs require continual patient education (Table 6), evaluation for drug 
interactions, and periodic laboratory monitoring (Table 3), all of which could be coordinated 
through institutional protocols or through ACs that facilitate initiation, compliance, transition 
between agents, and interruption for procedures.  
MANAGEMENT OF BLEEDING AND EMERGENCY CARE 
Even with the best coordinated care, bleeding complications will occur. Clinical trials comparing 
VKA with DOACs for stroke prevention in AF have shown an annual rate of major bleeding 
ranging from 2.1% to 3.6% of patients. Fatal bleeding occurs in up to 0.5% (33-36). Major 
bleeding is associated with higher mortality. In an analysis of 5 phase III clinical trials, 30-day 
mortality after a major bleeding episode was 13% with warfarin and 9% with dabigatran (37).  
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Minor bleeding may predict major bleeding (5, 38) and lead to discontinuation of effective 
anticoagulation therapy, underscoring the importance of both preventing and effectively 
managing bleeding episodes. With VKA therapy, regular monitoring and appropriate dose 
adjustment will improve anticoagulation quality and reduce bleeding. For DOACs, adjustment of 
dose based on renal function is crucial. With both VKA and DOACs, avoidance of concomitant 
aspirin and other antiplatelet agents, including long acting NSAIDs, whenever possible, is 
important.   
BLEEDING DEFINITIONS  
Bleeding severity in outpatient trials of anticoagulation was defined by the International Society 
on Thrombosis and Haemostasis (39) and has been revised (40). For this review those definitions 
have been modified to enhance their clinical relevance (Figure 1).  
GENERAL ASSESSMENT OF THE BLEEDING PATIENT RECEIVING OACT  
Management of the bleeding patient on an anticoagulant is outlined in Figure 2. Basic 
assessment includes determination of the site, onset, and volume of bleeding, and whether 
bleeding is ongoing. The time of last ingestion of the anticoagulant is especially important with 
DOACs. Concomitant medications should be reviewed (Table 3). An assessment of comorbid 
conditions and evidence of cardiac decompensation should be done. Laboratory assessment 
includes a CBC with platelet count, PT and aPTT, serum electrolytes and renal and hepatic 
function. 
LABORATORY MONITORING OF ANTICOAGULANTION 
VKA TREATED PATIENTS.  The prothrombin time (PT)/INR is essential to the assessment 
of the VKA-treated patient with bleeding. Invasive procedures to define and correct the bleeding 
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source are often delayed until the INR is reduced. The type and amount of reversal agent is often 
based on the degree of PT prolongation, although there are few data correlating clinical 
outcomes with the initial INR level and few data correlating clinical improvement with the use of 
reversal agents. 
DOAC TREATED PATIENTS.  Figure 3 summarizes the potential use of coagulation assays 
in the assessment of the bleeding patient taking a DOAC (41). A prolonged aPTT indicates an 
anticoagulant effect of dabigatran and a prolonged PT an anticoagulant effect of the FXa 
inhibitors. However, elevated plasma levels of dabigatran and FXa inhibitors may occur with 
normal aPTT or PT values, making them less useful in the assessment of the bleeding patient. 
Different PT and aPTT reagents vary widely in their sensitivity to the DOACs. 
Furthermore, there may be some danger in relying on conventional parameters to define reversal 
therapy in a bleeding patient receiving a DOAC. For example, an aPTT of > 2.5 times control 
suggests a supratherapeutic dabigatran concentration (42). A reversal agent may take several 
hours after ordering to reach the patient. Since the half-life of dabigatran is relatively short, by 
the time a reversal agent is administered, the reversal drug dose may be excessive, resulting in 
clotting. This highlights one of the difficulties in the design of clinical trials to assess reversal 
agents (43).  
The dilute thrombin time, a functional test of the effect of thrombin on fibrin formation, provides 
a reasonable estimate of dabigatran concentration across a wide range of drug levels (42), and is 
commercially available (Hemoclot). Ecarin-based assays, including the ecarin clotting time 
(ECT) and chromogenic ecarin assays, correlate well with dabigatran concentration, but are not 
widely available. 
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The anticoagulant effect of FXa inhibitors can be assessed by anti-FXa levels. Data linking anti-
FXa levels with bleeding and thrombosis related to FXa inhibitors are unavailable. Calibration of 
anti-factor Xa assays with specific FXa inhibitors is recommended.  
AGENTS TO REVERSE ANTICOAGULATION 
The introduction of DOACs has made therapy to reverse anticoagulation more complex. Newer 
agents (such as Prothrombin Complex Concentrate or PCC) are expensive and not always readily 
available. Many institutions have developed protocols for management of the patient treated with 
OACT who experiences major bleeding. Consultation with a hematologist is recommended. 
VITAMIN K. VKAs reduce the synthesis of functional vitamin K-dependent coagulation 
factors, providing a rationale for vitamin K therapy as a reversal agent. Intravenous (IV) vitamin 
K does not begin to reduce INR for 6 hours, often taking longer than 24 hours for complete 
reversal (44). IV vitamin K may result in allergic reactions (particularly when given as a bolus) 
and IV infusions should generally be limited to patients with major bleeding. Subcutaneous and 
intramuscular administration is not recommended. Oral vitamin K is used for minor bleeding 
with an elevated INR. Although effective at lowering the INR, there are few data demonstrating 
improvement in outcomes with vitamin K. High doses of vitamin K will prolong the time to 
achieve a therapeutic INR when warfarin is restarted. Vitamin K does not reverse the 
anticoagulant effect of DOACs. 
FRESH FROZEN PLASMA.  Fresh frozen plasma (FFP) and blood transfusion provide 
volume, a potential advantage in a volume-depleted patient, but a potential disadvantage in 
patients with heart failure or renal dysfunction. FFP is readily available, although there are 
delays associated with thawing frozen plasma. For a patient with a high INR who is actively 
bleeding, it may be necessary to administer > 1500 mL of FFP to meaningfully increase 
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coagulation factors. Even with reduction in INR, there are few data showing improvement in 
outcomes with FFP.  FFP in clinically feasible quantities does not reverse the anticoagulant 
effect of DOACs. 
PROTHROMBIN COMPLEX CONCENTRATE.  For patients with an elevated INR 
receiving VKA, a 10-30 minute infusion of prothrombin complex concentrate (PCC) improves 
INR values within minutes and lasts 12-24 hours.  The half- lives of infused factors are similar to 
endogenous factors. Vitamin K is generally recommended for use with PCC to sustain the 
reversal effect. 
The impact of PCC appears to be different with different DOACs. PCC did not normalize the 
aPTT, ecarin clotting time, and thrombin time in healthy volunteers who had received 
dabigatran, but immediately reversed a prolonged PT and an abnormal thrombin potential in 
rivaroxaban-treated healthy volunteers (45). Studies show that reversal of an anticoagulation 
effect can occur within 15 minutes, but may differ between direct thrombin inhibitors and FXa 
inhibitors.  Recent studies show that PCC reverses anticoagulant activity in healthy volunteers 
given either dabigatran or rivaroxaban within 2 hours (46). The composition of PCC varies with 
the manufacturer. Four-factor PCC contains factors II, VII, IX, and X. Three-factor PCC 
contains little or no factor VII.  In healthy volunteers who received rivaroxaban, 3-factor PCC 
restored thrombin generation better than 4-factor PCC, but4-factor PCC produced larger 
reductions in mean prothrombin time within 30 minutes. These discrepancies may be related to 
differences in factor concentration in these agents (47).  
Data linking improved clinical outcomes with the use of PCC in DOAC-treated patients are 
lacking. In addition there is concern about myocardial infarction and arterial thromboembolism 
with the more potent agents (48, 49) that must be balanced against potential benefits. Some 
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forms of PCC contain heparin, a concern in patients with heparin- induced thrombocytopenia. 
The dose of PCC is 20-50 units/kg and the wholesale cost is about $1.25/unit. 
OTHER REVERSAL AGENTS.  Recombinant factor VIIa has been effective for reversal of 
the anticoagulant effect of VKA (50-52).  Impact on laboratory parameters occurs within minutes 
and lasts 2-6 hr, but impact on bleeding consequences remains to be determined (53), and there is 
concern about the risk of thrombosis (48). 
Three additional reversal agents are currently being evaluated. Idarucizumab, a specific 
antibody to dabigatran (anti-Dabi Fab), has been reported to restore systemic blood 
coagulation in animal studies (43) and in healthy volunteers. The REVERSE-AD trial studying 
the use of this agent in uncontrolled bleeding is underway. Andexanet alfa, a modified FXa 
molecule that binds to FXa inhibitor allowing the patient’s intrinsic FXa to participate in 
coagulation, has been reported to provide rapid and near-complete reversal of factor X 
inhibitors in healthy volunteers. Aripazine, a small synthetic molecule with broad activity 
against heparin products and factor X agents is undergoing testing in healthy subjects (54). 
MANAGEMENT OF MAJOR BLEEDING 
Standard measures in the management of major bleeding in a patient taking an oral anticoagulant 
include fluid and blood resuscitation, identification and treatment of the bleeding source, and 
avoidance of administration of additional antithrombotics or antiplatelet drugs. Prompt reversal 
of the antithrombotic effects is desirable.  
VKAs.  Reversal of anticoagulation should be considered in a patient receiving VKAs who has 
major bleeding and an INR ≥ 1.5. Vitamin K 5-10 mg should be administered by slow IV 
infusion (14).  
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In 40 patients with a mean INR of 9.4, low dose 3-factor PCC (25 units/kg) and high dose 3-
factor PCC (50 units/kg) lowered the INR by 50% and 43% respectively (55). Adding plasma 
further reduced the INR by 89% and 88%. In another randomized study, 4-factor PCC was 
compared with fresh frozen plasma (FFP) in 219 nonsurgical patients with warfarin associated 
bleeding (mean INR 3.7). Within 1 hr of the start of infusion, more than two-thirds of the 4-
factor PCC group had an INR < 1.3 compared with none in the FFP group (56).  
The use of PCC is recommended as first line therapy in patients on VKAs with life threatening 
major bleeding (14). Doses can be repeated in 6 hr. Delays in the administration of PCC have 
been reported (57) perhaps reflecting lack of familiarity with new therapies or the lack of ready 
availability of these products.  
DOACs.  Gastric lavage could be considered for patients who experience major bleeding, if 
DOACs ingestion has been recent. Administration of activated charcoal may be helpful if the 
DOAC has been ingested within 2-6 hours (58). 
Data on patients treated with DOACs who have major bleeding are limited. Given the poor 
prognosis of major bleeding, especially CNS bleeding, in patients treated with DOACs, , some 
recommend PCC, activated PCC, or as a last choice activated factor VIIa to treat severe or life-
threatening bleeding (59).  However, there is no clinical evidence to support this 
recommendation.  
Because dabigatran is approximately 35% plasma bound, dialysis is a consideration in the event 
of major bleeding, particularly in the setting of renal insufficiency. Rivaroxaban, apixaban and 
edoxaban are highly protein bound and hemodialysis is likely to be ineffective.  
A high mortality rate associated with ICH occurs regardless of the type of anticoagulant. 
Measures to reverse the anticoagulant effect of VKAs have been shown to improve INR values 
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but not clinical outcomes. Agents to reverse the anticoagulant effect of DOACs are in 
development but there is concern that once ICH has occurred, even timely reversal of the 
anticoagulant effect may not improve clinical outcomes.  
MANAGEMENT OF CLINICALLY RELEVANT NON-MAJOR BLEEDING 
VKAs.  The use of reversal agents in patients with clinically relevant non-major bleeding 
depends on the age of the patient, the amount of bleeding, whether bleeding is ongoing, the INR, 
the severity of anemia, and co-morbid conditions of the patient. Oral vitamin K could be 
considered in this situation (14) but the risks of a prolonged period of time with subtherapeutic 
INR values must be weighed against the benefits.  Determining and treating the cause of 
bleeding is important, so that anticoagulation can be safely resumed. 
DOACs.  Given the short half- life of DOACs, the potential thrombotic risk of non-specific 
reversal agents, and the lack of evidence to support their use, reversal agents are not 
recommended for patients with clinically relevant non-major bleeding (59).  
MANAGEMENT OF MINOR BLEEDING OR ELEVATED INR VALUES 
VKAs.  In a patient with minor bleeding, decisions on warfarin dosing should be made 
dependent upon the INR.  
If the INR is > 10, management includes the following steps:  1) stop VKA therapy, 2) 
administer 2.5-5 mg of oral vitamin K (13), 3) monitor the INR every 12-14 hours, and 4) restart 
VKA therapy as INR approaches therapeutic range.  
If the patient is at high risk for bleeding based on advanced age, recent bleeding, anemia, heart 
failure, malignancy, renal dysfunction and other variables (60), oral vitamin K can be considered 
in the non-bleeding patient with an INR > 10. In a non-bleeding patient with an INR > 4.5 and < 
10, VKA should be held for 1 or 2 doses. Data on bleeding risk are conflicting in this situation 
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(61, 62).  Vitamin K is generally not recommended unless there are patient specific reasons that 
make bleeding more likely as previously outlined. 
DOACS.  DOACs have short half-lives, and for patients with minor bleeding, omitting several 
doses of the anticoagulant may be the only therapy required beyond local measures (e.g., 
applying pressure).  The duration of DOAC hiatus depends on the amount of bleeding and the 
thromboembolic risk. 
MANAGEMENT AFTER BLEEDING 
Patients recovering from major bleeding are frequently anemic, but are at risk for future bleeding 
(5). Resumption of anticoagulant therapy in such patients is problematic and yet, these patients 
may also be at high risk of thromboembolic events (63). In 1 study of 442 patients with a 
gastrointestinal bleed associated with warfarin, 260 (58.8%) restarted warfarin, sometimes as 
early as 4 days later (64). Those patients who did not resume warfarin had a higher risk of death 
and thromboembolic events. Similar findings were noted in patients after warfarin-associated 
CNS bleeding. Of 284 patients, 91 (32%) were re-started on warfarin prior to hospital discharge. 
Compared with those not started on warfarin, patients re-started on warfarin had lower mortality 
and had no increase in bleeding (65). After major bleeding, the location and severity of bleeding 
and whether the source of bleeding was effectively treated affects the decision of when and if 
anticoagulation should be re-started. 
VKA-TREATED PATIENTS.  If bleeding occurred in a VKA-treated patient with a high INR 
who is at high risk for stroke, a reasonable course of action after resolution of the bleeding 
episode might be to restart warfarin with careful follow-up of INR values. If a drug interaction 
with warfarin can be identified and avoided, VKAs can be restarted with more confidence. 
Alternatively, if the bleeding was not gastrointestinal or the TTR was low, it may be appropriate 
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to substitute a DOAC for warfarin therapy. Recent guidelines suggest the use of antiplatelet 
agents in this situation, although at a class IIb level (66). 
If bleeding occurs in a VKA treated patient with an INR of 2-3, the clinician should avoid the 
temptation to lower the INR goal, due to increased risk of thromboembolic events with an INR 
below 2 (67). In patients with bleeding and a normal INR, knowledge of the TTR (68) may be 
helpful.  
DOAC-TREATED PATIENTS.  Minor bleeding in a DOAC-treated patient presents a unique 
challenge. Reducing the dose of the DOAC also may reduce stroke prevention benefits. 
Changing to an alternative DOAC in cases of minor bleeding may be an option.  If minor 
gastrointestinal bleeding occurs in a patient on dabigatran or rivaroxaban, the patient should 
switch to apixaban, or edoxaban 30 mg since gastrointestinal bleeding is more common with 
dabigatran (33) and perhaps with rivaroxaban (34) than the other 2 agents. Other patients might 
benefit from a switch from a DOAC to a VKA.  
No clinical trials currently address the question of administration of either warfarin or a DOAC 
following major bleeding. However, if a patient at high risk for stroke has a major bleeding 
episode associated with VKA and a normal INR, alternative therapies might be considered. 
Clinical trials of direct thrombin inhibitors and FXa inhibitors in stroke prevention in AF have 
consistently shown a > 50% reduction in CNS bleeding with the newer agents compared with 
warfarin, although the mechanism is uncertain. 
CONCOMITANT COMPLEX DISEASE STATES THAT OCCUR IN AF PATIENTS ON 
OACT 
Patients with AF requiring OACT frequently have comorbid conditions that increase risks of 
bleeding, impact the risk benefit ratio of anticoagulation, or require additional therapy such as 
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antiplatelet agents. The evolution of therapy in such patients is on going. This is especially true 
with the use of DOACs plus anti-platelet therapy (either single or dual). 
Combining antiplatelet agents with anticoagulants increases the risk of bleeding. In the RE-LY 
trial (20) the risk of major bleeding increased from 2.8%/year to 4.8%/year when antiplatelet 
agents were added to warfarin. The risk of major bleeding was 2.6%/year with dabigatran 150 mg 
bid but increased to 4.4%/year with the addition of antiplatelet agents. A similar analysis from the 
ARISTOTLE trial noted increased bleeding when aspirin was used in conjunction with either 
warfarin or apixaban, although the absolute bleeding risk was higher with the combination of 
aspirin and warfarin compared with aspirin and apixaban (69).  
Two ongoing trials may inform the question. The Randomized Evaluation of Dual Therapy with 
Dabigatran vs. Triple Therapy Strategy with Warfarin in patients with non-valvular AF that have 
undergone PCI with stents (RE-DUAL PCI) will evaluate clinically relevant bleeding and 
thromboembolic events in patients treated with dabigatran plus a P2Y12 inhibitor compared with 
the current standard of warfarin plus dual antiplatelet therapy (DAPT). An Open-label, 
Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban 
and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial 
Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER-AF PCI) will compare 
clinically significant bleeding in 3 arms of therapy: (1) rivaroxaban 15 mg daily plus a P2Y12 
inhibitor, (2) rivaroxaban 2.5 mg bid plus a P2Y12 inhibitor and aspirin 75-100 mg daily, or (3) a 
VKA adjusted to an INR of 2-3, plus a P2Y12 inhibitor and aspirin 75-100 mg daily.  
RECENT CORONARY STENT AND NEW ONSET AF 
AF occurs in 5 to 10% of myocardial infarction patients and is associated with higher mortality 
compared to patients without AF (70). If stroke risk is low based on CHA2DS2-VASc score then 
20 
such patients could be treated with DAPT without the addition of anticoagulation. Observational 
data from the Danish registry (18) suggest that anticoagulants plus clopidogrel appear to be safer 
than triple therapy, although the efficacy of this combination has not been evaluated in 
randomized trials. Data from an open-label randomized trial in PCI patients (71) reported less 
bleeding and no increase in ischemic complications in patients treated with clopidogrel plus 
VKA compared with triple therapy. However, larger blinded studies are needed to confirm these 
findings. In patients who require triple therapy, the use of bare metal stents should be 
encouraged, and the duration of triple therapy kept as short as possible. 
ELECTIVE STENTING IN PATIENTS WITH ESTABLISHED AF ON 
ANTICOAGULANTS  
In patients with established AF on coumadin requiring elective stenting, concomitant 
glycoprotein IIb/IIIa inhibitors should generally be avoided. Radial access and bare metal 
stenting are preferred, as the former reduces access site bleeding and the latter minimizes the 
duration of triple therapy. As the duration of DAPT shortens with newer generation drug-eluting 
stents, this approach is changing and clinical trials are ongoing. Previously such patients may 
have been transitioned to warfarin, but these studies may affect this approach. If triple therapy 
(including VKA) is used low-dose aspirin plus clopidogrel is recommended in lieu of ticagrelor or 
prasugrel, since bleeding risks with VKA in conjunction with ticagrelor or prasugrel are higher 
than with clopidogrel. A lower target INR for warfarin (2.0-2.5) should be considered (72). A 
recent European Consensus paper (73) suggests a 3-phase approach in patients with AF and 
elective stenting. Patients at high stroke and high bleeding risk (CHA2DS2-VASc ≥ 2 and HAS-
BLED ≥3) should receive 4 weeks of triple therapy, up to 12 months of clopidogrel or aspirin 
plus an anticoagulant, and lifetime anticoagulation with or without an antiplatelet drug. Patients 
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at lower stroke and bleeding risk (CHA2DS2-VASc of 1 and HAS-BLED 0-2) should receive 4 
weeks to 6 months of triple therapy, up to 12 months of clopidogrel or aspirin plus an 
anticoagulant, and lifetime anticoagulation. 
ACUTE CORONARY SYNDROMES IN PATIENTS WITH ESTABLISHED AF ON 
ANTICOAGULANTS  
Low dose rivaroxaban (2.5 mg bid) for acute coronary syndromes (ACS) is approved in Europe 
as adjunctive therapy. This dose may not be optimal for the prevention of stroke in patients with 
AF, and rivaroxaban is not approved for this indication in the United States. Temporary 
discontinuation of DOAC should be considered in patients who are on DOACs at the time of an 
ACS, and if either ticagrelor or prasugrel is administered, since bleeding risks with these agents 
plus DOACs are unknown. Low dose is preferable to full dose aspirin. Bivalirudin may be a 
preferable acute anticoagulant, due to bleeding risk in the face of residual DOAC effect. 
Parenteral anticoagulation with heparin can be undertaken after DOAC effect has dissipated (16). 
Bare metal stenting and radial approach is preferable (59). Recent ACC/AHA ACS Guidelines 
state that anticoagulation may be interrupted at the time of procedure and that it “may be 
reasonable” to consider clopidogrel and anticoagulants in lieu of triple therapy (2). The 
European Consensus paper (74) suggested a similar 3 phase approach in ACS, with the patients 
at highest risk of both stroke and bleeding receiving 4 weeks of triple therapy followed by up to 
12 months of a single antiplatelet plus anticoagulation, and patients at low risk receiving 6 
months of triple therapy followed by up to 12 months of a single antiplatelet drug plus 
anticoagulation.  
PATIENTS WITH ESTABLISHED AF ON ANTICOAGULANTS WITH MEDICALLY 
MANAGED CORONARY DISEASE 
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Although patients with medically managed coronary artery disease following ACS may benefit 
from dual antiplatelet therapy, (74) treatment must be individualized in patients who are 
concomitantly on anticoagulants. The Warfarin-Aspirin Reinfarction II (WARIS II) Trial 
demonstrated a reduction in subsequent MI rates with warfarin and aspirin compared to warfarin 
alone (75), although it should be noted that this was not an AF trial. Data from the Atrial 
Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W) 
(76) also support the use of warfarin instead of antiplatelet therapy in stable CAD, by showing 
that the MI rate in AF patients assigned to warfarin was similar to those assigned to aspirin plus 
clopidogrel. In patients with stable CAD with AF and an ACS > 1 year previously, care should be 
individualized; single antiplatelet therapy or no antiplatelet therapy with anticoagulation may be 
preferred options (2). 
PATIENTS WHO DEVELOP AF > 1 MONTH AFTER BARE METAL STENT OR > 6 
MONTHS AFTER DRUG ELUTING STENT 
Data are conflicting about whether patients with stable CAD should be treated with a DOAC or 
warfarin alone, assuming this is warranted based on CHA2DS2-VASc score. In the RE-LY trial 
(31), there was a trend towards increased myocardial infarction, and meta-analysis suggested an 
association with direct thrombin inhibitors and myocardial infarction (77). However, ischemic 
events were not increased in RE-LY (78) and a “real world” Danish study of dabigatran use did 
not suggest an increased frequency of myocardial infarction (79). Similarly a survey of 134,414 
Medicare patients (37,587 patient-years) treated with dabigatran or warfarin for non valuvlar AF 
showed no increase in MI with dabigatran (80).  Figures 4a and 4b summarize 
recommendations for OACT with various coronary artery disease conditions. 
PATIENTS WITH CEREBRAL VASCULAR DISEASE AND ATRIAL AF 
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PATIENTS NOT PREVIOUSLY ON ANTICOAGULANTS.  Patients presenting with acute 
ischemic stroke or transient ischemic cerebral attack of presumed cardio-embolic origin should 
receive anticoagulation therapy. The timing and initiation of therapy depends upon the size of 
the stroke and the perceived risk of hemorrhagic transformation (66). In such patients, all 
DOACs may be preferable to warfarin because of the universally reduced risk of ICH. Although 
this is true in the convalescent phase of presumed thromboembolic stroke (after > 1 month) it 
has not been studied in the acute phase of such strokes. New AHA/ASA Guidelines recommend 
individualized therapy with VKA (Class 1, level of evidence A), apixaban (Class 1, level of 
evidence A, dabigatran (Class 1, level of evidence B) or rivaroxaban (Class IIa, level of evidence 
B) (81).  The European Society of Cardiology AF Guidelines suggest the use of DOAC over 
VKA in most patients with non-valvular AF based on net clinical benefit (Class IIa 
recommendation) (82). Because of the rapid onset of action, bridging therapy with low molecular 
weight heparin is not required. For patients unable to take anticoagulants, aspirin is an 
alternative option and the addition of clopidogrel might be reasonable. Two clinical trials of 
DOACs compared to aspirin in patients with embolic strokes of undetermined source (RE-
SPECT- ESUS [dabigatran] and NAVIGATE- ESUS) are currently recruiting patients) (83, 84). 
Previous studies have demonstrated a high prevalence of AF detected by prolonged monitoring in 
patients presenting with cryptogenic TIA or stroke (66, 85). Anticoagulation strategies in this 
subset of patients have not been rigorously tested for risk and benefit. 
PATIENTS PREVIOUSLY MAINTAINED ON OACT PRESENTING WITH ACUTE 
ISCHEMIC STROKE 
In patients previously maintained on DOACs, the balance of risks versus benefits of thrombolytic 
therapy for acute ischemic stroke is unclear. If there is uncertainty about the time since last 
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administration of the DOAC or if blood studies, e.g. PTT for dabigatran, or PT for FXa inhibitors 
indicate residual drug effect, thrombolysis should generally not be offered. In patients treated 
with warfarin, the risk of ICH with use of recombinant tissue plasminogen activator appears to be 
low when the INR is ≤1.7 (86). 
PATIENTS IN CONVALSCENT PHASE OF ISCHEMIC STROKE TREATED WITH 
VKAS  
In theory, patients presenting with an ischemic stroke and a therapeutic INR represent a drug 
failure of VKA and may be candidates for DOACs. Patients with stroke ≥ 2 weeks prior to 
presentation appear to have the same relative benefits of DOAC versus warfarin (87, 88). If early 
initiation of a DOAC is contemplated in a patient previously on warfarin it would seem prudent 
to allow the effect of warfarin to dissipate prior to initiating therapy. 
PATIENTS WITH HEMORRHAGIC STROKE ON OACT 
Hemorrhagic stroke is a complication of anticoagulant therapy. VKAs account for 12-14% of 
patients with ICH (89). Anticoagulants should be immediately discontinued and efforts to reverse 
anticoagulation undertaken as previously described. Although patients who develop hemorrhagic 
stroke on warfarin could theoretically be candidates for a DOAC in the convalescent phase, this 
hypothesis is untested, as most DOAC studies exclude patients with prior ICH. Package labeling 
for both VKAs and DOACs state that ICH is a contraindication for anticoagulation unless the 
cause of the hemorrhage has been identified and corrected. According to the stroke guidelines 
patients at high risk for recurrent hemorrhage may be considered candidates for antiplatelet 
therapy in lieu of anticoagulation. (Class IIB, level of evidence B) (66).  
PATIENTS WITH SIGNIFICANT CAROTID STENOSIS AND AF 
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Patients with carotid stenosis are often prescribed antiplatelet therapy for stroke prevention. At 
this time, it is unknown whether the addition of antiplatelet therapy improves outcomes compared 
to anticoagulation alone in patients with AF and carotid disease. Carotid endarterectomy for 
which single agent antiplatelet therapy is usually prescribed may be preferred over carotid artery 
stenting that requires DAPT (59, 90). More data are needed, and this topic is not addressed in the 
new stroke guidelines. 
PATIENTS WITH PERIPHERAL ARTERY DISEASE AND AF 
There are no data on the combination of DAPT and anticoagulation in patients with AF and 
peripheral artery disease managed with percutaneous intervention (90). Patients with medically 
managed peripheral artery disease are generally prescribed antiplatelet therapy. The addition of 
anticoagulation increases bleeding risk, as demonstrated in the WAVE Trial (89), in which patients 
with peripheral artery disease were assigned to warfarin plus an anti-platelet agent compared to an 
anti-platelet agent alone. Combined therapy was not associated with an improvement in the combined 
endpoints of MI, stroke, or cardiovascular death or MI, stroke, cardiovascular death or severe 
ischemia (coronary or peripheral arterial). The risk of life-threatening bleeding, however, occurred in 
4.0% of the combined group and 1.2% of the anti-platelet group. Therefore, risk benefit ratio needs to 
be estimated in deciding whether these patients should receive concomitant antiplatelet therapy and 
anticoagulation. Single antiplatelet therapy makes good clinical sense under these circumstances, 
since the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and 
Avoidance (CHARISMA) trial (91) of aspirin alone compared with clopidogrel plus aspirin in 
patients at high risk for cardiovascular events demonstrated that the addition of clopidogrel did not 
reduce the rate of the primary endpoint of MI, stroke, or cardiovascular death, but that bleeding 
increased with  DAPT. 
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THE USE OF DOACS IN PATIENTS WITH MECHANICAL HEART VALVES AND IN 
THE SETTING OF CARDIAC SURGERY 
The RE-ALIGN study tested high-dose dabigatran as an alternative to warfarin in patients with 
mechanical heart valves. This study was stopped early due to excessive bleeding and higher 
thromboembolic events in patients treated with dabigatran. The rapid onset of action of dabigatran 
in the postoperative cardiac surgery setting appears to pose a risk of serious bleeding, -particularly 
pericardial bleeding requiring reoperation. Until further results are available, the use of all the 
DOACs should be avoided for patients with mechanical prosthetic valves outside of a clinical 
trial. The FDA prescribing information for the DOACs are even more restrictive, stating that they 
should be avoided in all prosthetic valves, although DOACs were used in patients with 
bioprosthetic valves in several AF clinical trials. The data from RE-ALIGN with high-dose 
dabigatran raised concern for the use of these drugs in the immediate cardiac postoperative 
surgical setting (92). 
DOACS AT THE TIME OF CARDIOVERSION  
Patients who have AF or atrial flutter lasting > 48 hours are required to have therapeutic INR (2-
3) for 3-4 weeks prior to cardioversion regardless of method (pharmacological or electrical) or 
CHA2DS2-VASc score (2, 93-95). Alternatively, for patients who have not been on 3-4 weeks of 
continuous therapeutic VKAs, transesophageal echocardiography is reasonable prior to 
cardioversion (2, 96). With VKAs, awaiting therapeutic INRs weekly up to the time of 
cardioversion has led to delays in cardioversion (97).  
Three major randomized clinical trials have evaluated subsets of patients who underwent 
cardioversion (RELY, ROCKET AF, ARISTOTLE). A prospective study involving the use of 
rivaroxaban has also been published (98). In all studies the risk of stroke was low in the weeks 
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following cardioversion and was comparable to that with VKA. Of note is the fact that 
transesophageal echocardiography did not reduce the rate of thromboembolic events (99). 
Based on these data, for patients with AF or atrial flutter of unknown duration, or duration ≥ 48 hr 
anticoagulation with DOACs is required for ≥ 3 weeks prior to cardioversion and should be 
continued for ≥ 4 weeks post cardioversion (2).  
THE ROLE OF DOACS IN AF ABLATION 
Current recommendations for the prevention of stroke at the time of AF ablation are for continuous 
VKA (warfarin) anticoagulation with a low level therapeutic range (2.0-2.5). Because it is difficult 
to maintain an INR within this narrow range, DOACs may assume a more important role. Single 
and multicenter studies have examined the efficacy and safety of DOACs compared with 
uninterrupted warfarin in patients undergoing AF ablation (100-105). In general, centers and 
operators are either transitioning patients to warfarin for the periprocedural period or stopping the 
DOAC 1-2 days prior to procedure without bridging (106). 
A prospective matched multicenter observational study of 290 patients compared therapeutic 
warfarin (2-3.5) to dabigatran 150 mg bid for 3 weeks prior to ablation (with dabigatran held 
morning of procedure and resumed 3 hours post). A significant increase in composite bleeding and 
thromboembolic complications was noted with dabigatran (101). Several studies in which 
dabigatran was held at least 24 hours prior to procedure and restarted 4-22 hr later did not show 
any significant bleeding or thromboembolic complications compared to warfarin. These data 
suggest dabigatran should be interrupted ≥ 24 hours prior to the procedure in order to prevent 
significant bleeding (102-104).  
A multicenter, prospective study evaluated the safety and efficacy of rivaroxaban in comparison 
with uninterrupted warfarin therapy during AF ablation. Rivaroxaban was held 16 hours prior to 
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ablation and resumed 6 hours after hemostasis was obtained. There was no difference in major or 
minor bleeding complications. One TIA occurred in each group and no periprocedural stroke or 
mortality occurred in either group. The authors concluded rivaroxaban, with the dose held on the 
day of procedure, appears to be equally safe and effective when compared to uninterrupted 
warfarin (101). 
CONCLUSIONS 
Roundtable discussion of 4 major topics related to the integration of DOACs into clinical practice 
resulted in consensus in many areas, but questions and challenges in others. A poll of the 
participants was unanimous in the opinion that the stakeholder groups need to continue dialogue 
about the integration of these drugs into practice. Table 5 includes a list of unanswered questions 
is listed below. 
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FIGURE LEGENDS 
 
Central Illustration. Complex Interactions Surrounding the Anticoagulation Patient  
New drugs, such as the direct acting oral anticoagulants (DOACs) are tested for safety and 
efficacy in clinical trials involving specific patient populations with rigorous inclusion and 
exclusion criteria. Labels with prescribing instructions are written based on those trial data and 
data from a limited number of supporting trials using specific patient samples to test a limited 
number of drug interactions and a few select special patient populations. Once approved for use, 
these drugs are introduced into a much more complex system of care. Patients taking DOACs 
move between hospital care and outpatient care, and interact with many health care workers in a 
complex system. Patients taking DOACs have multiple co-morbidities, and take DOACs for long 
periods of time. Coordination of care is of the utmost importance to provide safe and effective 
management of oral anticoagulation in the modern healthcare environment. 
 
Figure 1. Definitions of Bleeding 
 
Figure 2. Acute Management of Bleeding in a Patient Receiving Oral Anticoagulation 
All patients receive a basic level of care (green box) with additional care provided depending 
upon the degree of bleeding (yellow and red boxes. 
apTT = activated partial thromboplastin time; CBC = complete blood count; CYP3A4 = 
Cytochrome P450 3A4; DOACs = direct oral anticoagulants; FFP = fresh frozen plasma; 
NSAIDs = nonsteroidal anti-inflammatory drugs; P-gp = P-glycoprotein; PT = prothombin time 
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Figure 3. Laboratory testing for anticoagulant activity.   
Red bars correspond to the approxiate range of detectability (i.e. sensitivity) and vertical 
hatching to the approximate range over which drug plasma levels may be quantified (i.e. 
linearity) of each assay to below, within, and above typical on-therapy plasma concentrations of 
DOACs (41). 
 
Figure 4a. Patients on Anticoagulants for AF Requiring Coronary Artery Stenting 
 
ACS = acute coronary syndrome; AF = atrial fibrilliation; ASA = aspirin; BMS = bare metal 
stent; INR = international normalized ratio; VKA = vitamin K antagonist 
 
Figure 4b. Patients on DAPT for Coronary Artery Stent who Develop AF 
 
ACS = acute coronary syndrome; AF = atrial fibrilliation; DAPT = dual antiplatelet therapy; 
DOAC = direct-acting oral anticoagulant; VKA = vitamin K antagonist 
 
Figure 5. Unanswered Questions 
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 Table 1. The 2009 Birmingham Schema Expressed as a Point-Based Scoring System, With 
the Acronym CHA2DS2–VASc 
Risk Factor Score 
Congestive heart failure or left ventricular dysfunction 1 
Hypertension  1 
Age ≥ 75 years old 2 
Diabetes mellitus 1 
Stroke or transient ischemic attack or thromboembolism  2 
Vascular disease (prior myocardial infarction, peripheral 
artery disease, or aortic plaque) 
1 
Age 65-74 years 1 
Sex category (i.e., female gender) 1 
Maximum total points 9 
Reprinted with permission from (107). 
 
 
Table 2. Summary of Selected DOACs Clinical Trials  
 RE-LY (33) 
N = 18,113 (3 
arms)*  
ROCKET-AF 
(34) 
N = 14,264  
ARISTOTLE 
(35) 
N = 18,201  
ENGAGE AF-
TIMI 48 (36) 
N = 
21,105 
(3arms)† 
Drug, dose  Dabigatran  
150 mg BID  
Rivaroxaban  
20 mg/daily  
Apixaban  
5 mg BID  
Edoxaban  
60/30 daily 
Adjusted dose?  No  Yes, at 
randomization 
only: 15 mg 
daily if  
CrCl 30-49 
mL/min  
Yes, at 
randomization 
only: 2.5 mg 
BID if two of:  
age ≥ 80 y, 
weight < 60 kg, 
SCr ≥ 1.5 
mg/dL  
Yes, at 
randomization and 
during study: Both 
doses halved if any 
1 of the following: 
CrCl 30-50 
mL/min, weight ≤ 
60 kg, use of 
verapamil, 
quinidine, or 
dronedarone 
Design  Randomized  
open-label  
Randomized 
double-blind, 
double-dummy  
Randomized 
double-blind,  
double-dummy  
Randomized 
double-blind, 
double-dummy 
Mean age, y  71.5  73  70  72  
Prior stroke/ 
transient ischemic 
20%  55%  19%  28%  
44 
attack/systemic 
embolism  
Mean CHADS2  2.2  3.5  2.1  2.8  
Warfarin-naïve  50.4%  37.6%  43%  41%  
Comparator  
Warfarin INR 2-3  
67% TTR 
(median)  
58% TTR 
(median) 
66% TTR 
(median) 
68% (median) 
 
Comparator  
Warfarin INR 2-3  
64% TTR 
(mean)  
55% TTR 
(mean) 
62% TTR 
(mean) 
65% (mean) 
 
Outcome (RR 
±95% CI) 
    
Stroke/Systemic 
embolism  
0.66 (0.53-
0.82)  
0.88 (0.75-
1.03)  
0.79 (0.66-
0.95)  
0.88 (0.75-1.03)  
Ischemic stroke  0.76 (0.60-
0.98)  
0.94 (0.75-
1.17)  
0.92 (0.74-
1.13)  
1.00 (0.83-1.19)  
Hemorrhagic 
stroke  
0.26 (0.14-
0.49)  
0.59 (0.37-
0.93)  
0.51 (0.35-
0.75)  
0.54 (0.38-0.77)  
Major bleeding  0.93 (0.81-
1.07)  
1.04 (0.90-
1.20)  
0.69 (0.60-
0.80)  
0.80 (0.71-0.91)  
Intracranial 
hemorrhage  
0.40 (0.27-
0.60)  
0.67 (0.47-
0.93)  
0.42 (0.30-
0.58)  
0.47 (0.34 -0.63)  
Gastrointestinal 
bleeding 
1.50 (1.19–
1.89)  
1.39 (1.19–
1.61)  
0.89 (0.70–
1.15)  
1.23 (1.02–1.50)  
Cardiovascular 
mortality  
0.85 (0.72-
0.99)  
0.89 (0.73-
1.10)  
0.89 (0.76-
1.04)  
0.86 (0.77-0.97)  
All-cause 
mortality  
0.88 (0.77-
1.00)  
0.85 (0.70-
1.02)  
0.89 (0.80-
0.998)  
0.92 (0.83-1.01)  
*Results are shown for dabigatran 150 mg BID. 
†Results are shown for edoxaban 60 mg daily 
Estimate Creatinine Clearance (CrCL) using Cockcroft-Gault formula:  
(140-age)x(weight in kg)x(0.85 if female)/(72)x(creatinine in mg/dL) 
 
 
 
 
 
 
 
Table 3. FDA Approved Direct Acting Oral Anticoagulants for Non-Valvular Arial 
Fibrillation* 
 Dabigatran 
(Pradaxa®) (108) 
Rivaroxaban 
(Xarelto®) 
(109) 
Apixaban 
(Eliquis®) (110) 
Edoxaban 
(Savaysa®) (24) 
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Mechanism of 
Action 
 
Direct Thrombin 
Inhibitor 
 
Factor Xa 
Inhibitor 
 
Factor Xa 
Inhibitor 
 
Factor Xa 
Inhibitor 
 
Dosing for 
Non-Valvular 
AF† 
 
150 mg twice daily 
 
20 mg daily with 
evening meal 
 
5 mg twice daily 
If CrCL‡ > 50 
mL/min to < 95 
mL/min: 60 mg 
daily  
 
 
Dosing 
considerations 
for Non-
Valvular AF 
with renal 
adjustments 
 
If CrCL‡ is 15-30 
mL/min: 75 mg 
twice daily  
 
If CrCL is < 15 
mL/min: Avoid 
use 
 
If CrCL‡ is 15-
50 mL/min: 15 
mg daily with 
evening meal  
 
 
 
If the patient 
has at least 2 of 
the following: 
- Age ≥ 80 years 
old 
- Weight ≤ 60 kg 
- SCr ≥ 1.5 
mg/dL: 2.5 mg 
twice daily  
 
If CrCL‡ > 95 
mL/min: do not 
use; may have 
an increased risk 
of ischemic 
stroke as 
compared to 
warfarin 
 
If CrCL‡ 15-50 
mL/min: 30 mg 
daily 
 
 
Dosing 
considerations 
for Non-
Valvular AF 
with hepatic 
adjustments 
 
Administration in 
patients with 
moderate hepatic 
impairment (Child-
Pugh B) showed 
no evidence of 
change in exposure 
or 
pharmacodynamics 
 
Avoid use in 
patients with 
Child-Pugh B 
and C hepatic 
impairment or 
with any degree 
of hepatic 
impairment 
associated with 
coagulopathy 
 
Mild hepatic 
impairment: No 
dose adjustment 
needed 
Moderate 
hepatic 
impairment: No 
dosing 
recommendation 
available 
Severe hepatic 
impairment: 
Avoid use 
 
Avoid use in 
patients with 
Child-Pugh B 
and C hepatic 
impairment  
 
Drug 
Interactions 
 
 
Avoid concomitant 
use with P-gp 
inducers (e.g., 
rifampin). 
 
P-gp inhibitors and 
impaired renal 
function can lead 
to increased 
 
Avoid 
concomitant use 
with strong dual 
inhibitors of 
CYP3A4 and P-
gp (e.g., 
ketoconazole, 
ritonavir, 
erythromycin) or 
 
Avoid 
concomitant use 
with strong dual 
inhibitors of 
CYP3A4 and P-
gp (e.g., 
ketoconazole, 
ritonavir, 
erythromycin) or 
 
Avoid 
concomitant use 
with P-gp 
inducers (e.g., 
rifampin) 
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exposure to 
dabigatran: avoid 
concomitant use 
with severe renal 
impairment (<  
30mL/min); for 
moderate renal 
impairment reduce 
dose to 75mg 
twice daily when 
used 
concomitantly with 
dronedarone or 
systemic 
ketoconazole 
reduce apixaban 
dose 
 
Avoid 
concomitant use 
with strong dual 
inducers of 
CYP3A4 and P-
gp (e.g., 
rifampin, 
phenytoin, 
carbamazepine) 
 
Avoid 
concomitant use 
with other 
anticoagulants 
reduce apixaban 
dose 
 
Avoid 
concomitant use 
with strong dual 
inducers of 
CYP3A4 and P-
gp (e.g., 
rifampin, 
phenytoin, 
carbamazepine) 
 
Concomitant use 
with antiplatelet 
agents, 
fibrinolytics, 
heparin, aspirin, 
and chronic 
NSAID 
increases 
bleeding risk 
Major 
Adverse 
Effects  
Dyspepsia, 
bleeding 
Bleeding  Bleeding  Bleeding 
 
Monitoring§ 
 
Baseline laboratory assessment: Hemoglobin/hematocrit, liver function, renal 
function, PT/INR 
At every visit: Adherence, signs/symptoms of bleeding or thromboembolism, 
side effects, concomitant medications (including over-the-counter) 
Annual laboratory assessment: Hemoglobin/hematocrit, renal function, liver 
function 
If CrCl 30-60 mL/min, > 75 years old, or fragile: renal function q 6 months 
If CrCl 15-30 mL/min: renal function q 3 months 
If condition changes that might impact anticoagulation therapy: check renal 
and/or liver function 
*Other indications for these agents are not included in this table. Refer to the prescribing 
information for complete information 
† May need to adjust dose or avoid based on concomitant medications.  
‡ Estimate Creatinine Clearance (CrCL) using Cockcroft-Gault formula:  
(140-age)x(weight in kg)x(0.85 if female)/(72)x(creatinine in mg/dL) 
 
§ Adapted from (16) 
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AF=atrial fibrillation; CrCL= Creatinine Clearance; CYP3A4=Cytochrome P450 3A4; 
INR=International Normalized Ratio; NSAID=Nonsteroidal anti-inflammatory drug; P-gp=P-
glycoprotein; PT=Prothrombin Time. 
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Table 4. Selected Drug Interactions with Direct Acting Oral Anticoagulants* 
 Mechanis
m of 
Drug 
Interactio
n 
Dabigatra
n 
(Pradaxa
®) (108) 
Rivaroxaban 
(Xarelto®) 
(109) 
Apixaban 
(Eliquis®) 
(110) 
Edoxaban 
(Savaysa®) 
(24) 
Carbamazepi
ne 
Strong 
inducer of 
CYP3A4 
and P-gp 
Avoid use Avoid use Avoid use No specific 
recommendatio
ns 
Clarithromyc
in 
Strong 
inhibition 
of 
CYP3A4 
and P-gp 
No 
adjustment 
needed 
No adjustment 
needed 
Reduce dose 
from 5mg 
twice daily to 
2.5mg twice 
daily 
 
If on 2.5mg 
twice daily, 
discontinue 
apixaban 
No specific 
recommendatio
ns 
Dronedarone P-gp 
inhibitor 
With 
CrCL 30-
50 mL 
/min, 
reduce 
dose to 
75mg 
twice daily 
No specific 
recommendatio
ns 
No specific 
recommendatio
ns 
No adjustment 
needed  
Itraconazole Strong 
inhibition 
of 
CYP3A4 
and P-gp 
No 
adjustment 
needed 
Avoid use Reduce dose 
from 5mg 
twice daily to 
2.5mg twice 
daily 
 
If on 2.5mg 
twice daily, 
discontinue 
apixaban 
No specific 
recommendatio
ns 
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Ketoconazole Strong 
inhibition 
of 
CYP3A4 
and P-gp 
With 
CrCL 30-
50 
mL/min, 
reduce 
dose to 
75mg 
twice daily 
Avoid use Reduce dose 
from 5mg 
twice daily to 
2.5mg twice 
daily 
 
If on 2.5mg 
twice daily, 
discontinue 
apixaban 
No specific 
recommendatio
ns 
Phenytoin Strong 
inducer of 
CYP3A4 
and P-gp 
Avoid use Avoid use Avoid use No specific 
recommendatio
ns 
Rifampin Strong 
inducer of 
CYP3A4 
and P-gp 
Avoid use Avoid use Avoid use Avoid use 
Ritonavir Strong 
inhibition 
of 
CYP3A4 
and P-gp 
No 
adjustment 
needed 
Avoid use Reduce dose 
from 5mg 
twice daily to 
2.5mg twice 
daily 
 
If on 2.5mg 
twice daily, 
discontinue 
apixaban 
No specific 
recommendatio
ns 
St. John’s 
wort 
Strong 
inducer of 
CYP3A4 
and P-gp 
Avoid use Avoid use Avoid use No specific 
recommendatio
ns 
* This is not a comprehensive list of all drug interactions. Please refer to individual medication 
manufacturer prescribing information for complete information 
Estimate Creatinine Clearance (CrCL) using Cockcroft-Gault formula:  
(140-age)x(weight in kg)x(0.85 if female)/(72)x(creatinine in mg/dL) 
 
CYP3A4 = Cytochrome P450 3A4; P-gp = P-glycoprotein; CrCL = Creatinine Clearance 
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Table 5. Transitioning between Anticoagulants and Interruption of Therapy* 
Conversion Apixaban 
(Eliquis®) 
(110) 
Rivaroxaban 
(Xarelto®) 
(109) 
Dabigatran 
(Pradaxa®) (108) 
Edoxaban 
(Savaysa®) (24) 
From 
Warfarin to 
DOAC 
Stop warfarin 
and start 
apixaban when 
INR < 2 
Stop warfarin 
and start 
rivaroxaban 
when INR < 
3(109) 
Stop warfarin, start 
dabigatran when 
INR < 2 
Stop warfarin 
and start 
edoxaban when 
INR ≤ 2.5  
From DOAC 
to Warfarin‡ 
Stop apixaban 
and start 
warfarin and 
parenteral 
anticoagulant 
when next dose 
of apixaban 
would be due; 
discontinue 
parenteral 
agent when 
INR in 
therapeutic 
range 
 
 
Stop rivaroxaban 
and start 
warfarin and 
parenteral 
anticoagulant 
when next dose 
of rivaroxaban 
would be due; 
discontinue 
parenteral agent 
when INR in 
therapeutic range 
 
 
If CrCL ≥ 
50mL/min, start 
warfarin 3 days 
before stopping 
dabigatran 
 
If CrCL 30-50 
mL/min, start 
warfarin 2 days 
before stopping 
dabigatran 
 
If CrCL 15-30 
mL/min, start 
warfarin 1 day 
before stopping 
dabigatran 
 
If CrCl < 15 
mL/min, no 
available 
recommendation 
Oral option: 
Reduce 
edoxaban dose 
by 50% and start 
warfarin; check 
INR at least 
weekly and just 
prior to 
edoxaban dose. 
When INR > 2, 
discontinue 
edoxaban.  
 
Parenteral 
option: Stop 
edoxaban; start 
parenteral 
anticoagulant 
and warfarin at 
time the next 
dose of 
edoxaban would 
be due. When 
INR > 2, 
discontinue 
edoxaban. 
 
From 
Parenteral 
Agent to 
DOAC 
Discontinue 
parenteral 
agent; start 
apixaban at the 
time the next 
dose of 
parenteral 
agent would be 
due 
LMWH: 
Discontinue 
LMWH; start 
rivaroxaban 0-2 
hours before 
next scheduled 
evening dose of 
LMWH and 
omit 
LMWH: 
Discontinue 
LMWH; start 
dabigatran 0-2 
hours before the 
time the next dose 
of LMWH would 
be due. 
 
LMWH: 
Discontinue 
LMWH; start 
edoxaban at the 
time the next 
dose of LMWH 
would be due. 
 
Unfractionated 
heparin 
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administration of 
LMWH 
 
Unfractionated 
heparin 
intravenous 
infusion: Initiate 
rivaroxaban 
when 
discontinuing 
heparin infusion 
Unfractionated 
heparin 
intravenous 
infusion: Initiate 
dabigatran when 
discontinuing 
heparin infusion 
intravenous 
infusion: Initiate 
edoxaban 4 
hours after 
discontinuing 
heparin infusion 
From DOAC 
to Parenteral 
Anticoagulant 
Discontinue 
apixaban; start 
parenteral 
agent at the 
time the next 
dose of 
apixaban 
would be due 
Discontinue 
rivaroxaban; 
start parenteral 
agent at the time 
the next dose of 
rivaroxaban 
would be due 
If CrCL ≥ 30 
mL/min; 
discontinue 
dabigatran; start 
parenteral agent 12 
hours after last 
dabigatran dose 
 
If CrCL < 30 
mL/min; 
discontinue 
dabigatran; start 
parenteral agent 24 
hours after last 
dabigatran dose 
Discontinue 
edoxaban; start 
parenteral agent 
at the time the 
next dose of 
edoxaban would 
be due 
From DOAC 
to DOAC 
Discontinue 
apixaban; start 
DOAC at the 
time the next 
dose of 
apixaban 
would be due 
Discontinue 
rivaroxaban; 
start DOAC at 
the time the next 
dose of 
rivaroxaban 
would be due 
No information 
available; consider 
patient specific 
characteristics (eg., 
renal function, risk 
of bleeding or 
stroke) 
Discontinue 
edoxaban; start 
DOAC at the 
time the next 
dose of 
edoxaban would 
be due 
Temporary 
Interruption of 
DOAC for 
Surgery and 
Other Invasive 
Procedures 
Moderate – 
High Risk 
Bleeding: 
Discontinue at 
least 48 hours 
prior to surgery 
or invasive 
procedure 
 
Low Risk 
Bleeding: 
Discontinue at 
least 24 hours 
Discontinue at 
least 24 hours 
prior to surgery 
or invasive 
procedure 
If CrCl ≥ 50 
mL/min: 
Discontinue at 
least 1-2 days prior 
to surgery or 
invasive procedure 
 
If CrCL < 50 
mL/min: 
Discontinue at 
least 3-5 days prior 
to surgery or 
invasive procedure 
Discontinue at 
least 24 hours 
prior to surgery 
or invasive 
procedure 
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prior to surgery 
or invasive 
procedure 
* Refer to the prescribing information for complete information 
‡ DOACs can impact INR so INR monitoring during conversion from DOAC to warfarin is 
not clinically useful  
DOAC=Direct Acting Oral Anticoagulants; CrCL=Creatinine Clearance; INR=International 
Normalized Ratio 
Estimate Creatinine Clearance (CrCL) using Cockcroft-Gault formula:  
(140-age)x(weight in kg)x(0.85 if female)/(72)x(creatinine in mg/dL) 
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Table 6. Education Topics for Oral Anticoagulants  
VKA and DOACS  
Anticoagulation 
basics Reason for anticoagulation 
 How medication reduces AF complications 
 Generic, trade names 
 Onset, duration of action 
 Duration of therapy 
 Reversibility 
 Storage 
Adherence When to take doses 
 What to do if a dose is missed 
 Do not run out of this medication; consequence of non-adherence 
 Consequence of taking too much 
Risk and benefits Common signs and symptoms of clot; what to do if they occur 
 Common signs and symptoms of bleeding; what to do if they occur 
 Need for birth control in women of childbearing age 
Preventative care Precautionary measures to minimize risk of trauma or bleeding 
 Potential drug interactions; which providers to notify when 
medication 
 Regimen changes 
Alcohol Avoid/limit alcohol intake 
Aspirin Avoid unless clearly indicated 
NSAIDs Avoid or minimize use 
Self-care Common adverse effects, allergic reactions 
Accessing 
healthcare Which providers to notify of anticoagulant use 
 Which providers to notify when dental, surgical, invasive procedures 
are scheduled 
 Carrying identification (medication bracelet or necklace, wallet card) 
General 
laboratory 
monitoring 
Frequency, what will be checked  
Dabigatran Only  
Adherence Swallow whole, do not break, crush, or open capsule. Take with full glass of water. 
Storage Keep in original container; do not put in pillbox (do not discard desiccant) 
Self-care May increase GI upset; discuss with clinician if bothersome. 
54 
Rivaroxaban Only  
Adherence Take with food (evening meal) 
VKA Only  
Diet Influence of dietary vitamin K, need for consistency 
INR monitoring Meaning, significance, target 
 Frequency 
AF = atrial fibrillation; DOACs = direct-acting oral anticoagulants (apixaban, dabigatran, 
rivaroxaban); GI = gastrointestinal; INR = international normalized ratio; NSAIDs = Non-
steroidal anti-inflammatory agents. VKA = Vitamin K Antagonist.  
